Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 28;12(4):669-675.
doi: 10.21037/tlcr-23-74. Epub 2023 Apr 4.

Evaluating the intracranial activity of adagrasib

Rupesh Kotecha  1   2 , Alonso La Rosa  1 , Tugce Kutuk  1 , Manmeet S Ahluwalia  2   3 , Minesh P Mehta  1   2
Affiliations
Editorial

Evaluating the intracranial activity of adagrasib

Rupesh Kotecha et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Brain metastases; KRASG12C mutation; adagrasib; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-74/coif). RK received personal fees from Accuray Inc., Elekta AB, ViewRay Inc., Novocure Inc., Elsevier Inc., Brainlab, Kazia Therapeutics, Castle Biosciences, and institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, and Kazia Therapeutics. MSA received research grants from AstraZeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, MimiVax, Merck, Seagen; and received consulting fees from Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix; served on scientific advisory board on Cairn Therapeutics, Pyramid Biosciences, Modifi Biosciences; and is a stock shareholder in Mimivax, Cytodyn, MedInnovate Advisors LLC. MPM received consulting fees from Karyopharm, Sapience, Zap-X, Mevion, Xoft, and Kazia Therapeutics; and served on the BOD of Oncoceutics and Xcision, and served on Advisory Board of Mevion and served as the Brain Tumor Committee Chair of NCCTN Group of NRG Oncology, and hold stocks in Chimerix. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Published intracranial response rates for various systemic therapies using in patients with brain metastasis from NSCLC (31,32). EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, c-ROS oncogene 1; RET, rearranged during transfection; NTRK, neurotrophic tyrosine kinase; NSCLC, non-small cell lung cancer.
See this image and copyright information in PMC

Comment on

References

    1. Suh JH, Kotecha R, Chao ST, et al. Current approaches to the management of brain metastases. Nat Rev Clin Oncol 2020;17:279-99. 10.1038/s41571-019-0320-3 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol 2015;33:1881-8. 10.1200/JCO.2014.59.0539 - DOI - PMC - PubMed
    1. Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;118:4502-11. 10.1002/cncr.27409 - DOI - PMC - PubMed
    1. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108-11. 10.1016/j.lungcan.2015.01.020 - DOI - PMC - PubMed